The value of deprescribing in older adults with dementia: a narrative review
Expert Rev Clin Pharmacol. 2021 Jul 26. doi: 10.1080/17512433.2021.1961576. Online ahead of print.ABSTRACTIntroduction: Mitigating the burden of unnecessary polypharmacy or multiple medication use in people living with dementia has been recognized as a key priority internationally. One approach to reducing inappropriate polypharmacy is through medication withdrawal or deprescribing. The aim of this narrative review is to appraise current evidence on the safety and efficacy of deprescribing in older people with dementia.Area covered: Non-systematic searches of key databases including PubMed, Embase and Google Scholar were c...
Source: Expert Review of Clinical Pharmacology - July 27, 2021 Category: Drugs & Pharmacology Authors: Mouna J Sawan Daniela C Moga Megan J Ma Joanna C Ng Kristina Johnell Danijela Gnjidic Source Type: research

131-I-metaiodobenzylguanidine and chemotherapy for advanced neuroblastoma
Expert Rev Clin Pharmacol. 2021 Jul 27. doi: 10.1080/17512433.2021.1960821. Online ahead of print.NO ABSTRACTPMID:34311635 | DOI:10.1080/17512433.2021.1960821 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 27, 2021 Category: Drugs & Pharmacology Authors: Stefano Mastrangelo Giorgio Attin à Antonio Ruggiero Source Type: research

Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations
Expert Rev Clin Pharmacol. 2021 Jul 27. doi: 10.1080/17512433.2021.1961578. Online ahead of print.ABSTRACTINTRODUCTION: : Severe infections continue to impose a major burden on critically ill children and mortality rates remain stagnant. Outcomes rely on accurate and timely delivery of antimicrobials achieving target concentrations in infected tissue. Yet, developmental aspects, disease-related variables, and host factors may severely alter antimicrobial pharmacokinetics in pediatrics. The emergence of antimicrobial resistance increases the need for improved treatment approaches.AREAS COVERED: : This narrative review explo...
Source: Expert Review of Clinical Pharmacology - July 27, 2021 Category: Drugs & Pharmacology Authors: Quyen Tu Menino Cotta Sainath Raman Nicolette Graham Luregn Schlapbach Jason A Roberts Source Type: research

The value of deprescribing in older adults with dementia: a narrative review
Expert Rev Clin Pharmacol. 2021 Jul 26. doi: 10.1080/17512433.2021.1961576. Online ahead of print.ABSTRACTIntroduction: Mitigating the burden of unnecessary polypharmacy or multiple medication use in people living with dementia has been recognized as a key priority internationally. One approach to reducing inappropriate polypharmacy is through medication withdrawal or deprescribing. The aim of this narrative review is to appraise current evidence on the safety and efficacy of deprescribing in older people with dementia.Area covered: Non-systematic searches of key databases including PubMed, Embase and Google Scholar were c...
Source: Expert Review of Clinical Pharmacology - July 27, 2021 Category: Drugs & Pharmacology Authors: Mouna J Sawan Daniela C Moga Megan J Ma Joanna C Ng Kristina Johnell Danijela Gnjidic Source Type: research

131-I-metaiodobenzylguanidine and chemotherapy for advanced neuroblastoma
Expert Rev Clin Pharmacol. 2021 Jul 27. doi: 10.1080/17512433.2021.1960821. Online ahead of print.NO ABSTRACTPMID:34311635 | DOI:10.1080/17512433.2021.1960821 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 27, 2021 Category: Drugs & Pharmacology Authors: Stefano Mastrangelo Giorgio Attin à Antonio Ruggiero Source Type: research

Molecular docking and dynamics study to explore phytochemical ligand molecules against the main protease of SARS-CoV-2 from extensive phytochemical datasets
CONCLUSIONS: Our combinatorial drug design approaches may help researchers to identify suitable drug candidates against SARS-CoV-2.PMID:34301158 | DOI:10.1080/17512433.2021.1959318 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 24, 2021 Category: Drugs & Pharmacology Authors: Shafi Mahmud Mohasana Akter Mita Suvro Biswas Gobindo Kumar Paul Maria Meha Promi Shamima Afrose Robiul Hasan Sharmin Sultana Shimu Shahriar Zaman Salah Uddin Trina Ekawati Tallei Talha Bin Emran Abu Saleh Source Type: research

Lenvatinib: Established and Promising Drug for the Treatment of Advanced Hepatocellular Carcinoma
Expert Rev Clin Pharmacol. 2021 Jul 22. doi: 10.1080/17512433.2021.1958674. Online ahead of print.ABSTRACTINTRODUCTION: : The evolving therapeutic landscape of advanced hepatocellular carcinoma (HCC) includes the increasing implementation of target-therapy and immunotherapy. Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma. Its approval has changed the scenario of first-line therapies for advanced HCC, where just sorafenib proved clinical efficacy for over a decade.AREAS COVERED: : The current evidence on the role of lenvatinib for patients with adva...
Source: Expert Review of Clinical Pharmacology - July 22, 2021 Category: Drugs & Pharmacology Authors: Martina Catalano Andrea Casadei-Gardini Gianmarco Vannini Claudia Campani Fabio Marra Enrico Mini Giandomenico Roviello Source Type: research

Therapeutic approach to difficult-to-treat typical absences and related epilepsy syndromes
Expert Rev Clin Pharmacol. 2021 Jul 21. doi: 10.1080/17512433.2021.1959317. Online ahead of print.ABSTRACTINTRODUCTION: typical absences (TAs), are brief, generalized epileptic seizures of abrupt onset and termination clinically manifesting with impairment of awareness and associated with 3 Hz spike-wave discharges on EEG. TAs may occur in different idiopathic generalized epilepsies (IGE). Despite treatment with adequate anti-seizure medications (ASMs), TAs may persist in ~25% of subjects. This narrative review focuses on the therapeutic approach to difficult-to-treat TAs occurring in the setting of IGE.AREAS COVERED: a li...
Source: Expert Review of Clinical Pharmacology - July 22, 2021 Category: Drugs & Pharmacology Authors: Giovanni Mastroianni Michele Ascoli Sara Gasparini Francesco Brigo Vittoria Cianci Sabrina Neri Emilio Russo Umberto Aguglia Edoardo Ferlazzo Source Type: research

Lenvatinib: Established and Promising Drug for the Treatment of Advanced Hepatocellular Carcinoma
Expert Rev Clin Pharmacol. 2021 Jul 22. doi: 10.1080/17512433.2021.1958674. Online ahead of print.ABSTRACTINTRODUCTION: : The evolving therapeutic landscape of advanced hepatocellular carcinoma (HCC) includes the increasing implementation of target-therapy and immunotherapy. Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma. Its approval has changed the scenario of first-line therapies for advanced HCC, where just sorafenib proved clinical efficacy for over a decade.AREAS COVERED: : The current evidence on the role of lenvatinib for patients with adva...
Source: Expert Review of Clinical Pharmacology - July 22, 2021 Category: Drugs & Pharmacology Authors: Martina Catalano Andrea Casadei-Gardini Gianmarco Vannini Claudia Campani Fabio Marra Enrico Mini Giandomenico Roviello Source Type: research

Therapeutic approach to difficult-to-treat typical absences and related epilepsy syndromes
Expert Rev Clin Pharmacol. 2021 Jul 21. doi: 10.1080/17512433.2021.1959317. Online ahead of print.ABSTRACTINTRODUCTION: typical absences (TAs), are brief, generalized epileptic seizures of abrupt onset and termination clinically manifesting with impairment of awareness and associated with 3 Hz spike-wave discharges on EEG. TAs may occur in different idiopathic generalized epilepsies (IGE). Despite treatment with adequate anti-seizure medications (ASMs), TAs may persist in ~25% of subjects. This narrative review focuses on the therapeutic approach to difficult-to-treat TAs occurring in the setting of IGE.AREAS COVERED: a li...
Source: Expert Review of Clinical Pharmacology - July 22, 2021 Category: Drugs & Pharmacology Authors: Giovanni Mastroianni Michele Ascoli Sara Gasparini Francesco Brigo Vittoria Cianci Sabrina Neri Emilio Russo Umberto Aguglia Edoardo Ferlazzo Source Type: research

Targeting the spectrum of immune checkpoints in prostate cancer
Expert Rev Clin Pharmacol. 2021 Jul 15:1-14. doi: 10.1080/17512433.2021.1949287. Online ahead of print.ABSTRACTIntroduction: The proven efficacy of the cellular vaccine sipuleucel-T in 2010 led to optimism about immunotherapeutic approaches for the treatment of prostate cancer. Some surmised that prostate cancer might be an ideal target for immune-mediated killing given that the prostate is not an essential organ and expresses unique proteins including prostate-specific antigen, prostate-specific membrane antigen, and prostatic acid phosphatase that could be targeted without side effects. Subsequently, antibodies that inhi...
Source: Expert Review of Clinical Pharmacology - July 15, 2021 Category: Drugs & Pharmacology Authors: Laura A Sena Samuel R Denmeade Emmanuel S Antonarakis Source Type: research

Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
Expert Rev Clin Pharmacol. 2021 Jul 7:1-12. doi: 10.1080/17512433.2021.1947796. Online ahead of print.ABSTRACTIntroduction: Healthcare providers (HCPs) see many patients with obesity-related complications and are therefore well placed to help treat obesity itself. However, limited collated information exists to help HCPs with the practical use of anti-obesity medications (AOMs). We focus on the initiation and maintenance of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight management, liraglutide 3.0 mg. Literature search was conducted between 25-28 November 2019 on PubMed and ClinicalTrials.gov.Areas covere...
Source: Expert Review of Clinical Pharmacology - July 7, 2021 Category: Drugs & Pharmacology Authors: Dhiren Patel April Smith Source Type: research

Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomised controlled trials
Expert Rev Clin Pharmacol. 2021 Jul 6. doi: 10.1080/17512433.2021.1951473. Online ahead of print.NO ABSTRACTPMID:34227438 | DOI:10.1080/17512433.2021.1951473 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 6, 2021 Category: Drugs & Pharmacology Authors: Eduardo Ekman Schenberg Source Type: research

Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent
Expert Rev Clin Pharmacol. 2021 Jul 6:1-10. doi: 10.1080/17512433.2021.1932460. Online ahead of print.ABSTRACTINTRODUCTION: Hyperkalemia is a common finding in patients with advanced kidney disease for multiple reasons. Renin-Angiotensin-Aldosterone-System Inhibitors (RAASi) that are indicated for slowing down progression of kidney disease are often associated with hyperkalemia which becomes a limiting factor in their use and titration to the maximum dose. Having a safe, effective, tolerable, and affordable potassium binder can help optimize RAAS inhibition in the setting of kidney disease.AREAS COVERED: Although sodium po...
Source: Expert Review of Clinical Pharmacology - July 6, 2021 Category: Drugs & Pharmacology Authors: Anjay Rastogi Ramy M Hanna Anita Mkrttchyan Maham Khalid Sinan Yaqoob Kelly Shaffer Puneet Dhawan Niloofar Nobakht Mohammad Kamgar Ray Goshtaseb Kristine Sarmosyan Mariarosaria Gnarini Olivia Wassef Edgar Lerma Source Type: research

Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomised controlled trials
Expert Rev Clin Pharmacol. 2021 Jul 6. doi: 10.1080/17512433.2021.1951473. Online ahead of print.NO ABSTRACTPMID:34227438 | DOI:10.1080/17512433.2021.1951473 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 6, 2021 Category: Drugs & Pharmacology Authors: Eduardo Ekman Schenberg Source Type: research

Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent
Expert Rev Clin Pharmacol. 2021 Jul 6:1-10. doi: 10.1080/17512433.2021.1932460. Online ahead of print.ABSTRACTINTRODUCTION: Hyperkalemia is a common finding in patients with advanced kidney disease for multiple reasons. Renin-Angiotensin-Aldosterone-System Inhibitors (RAASi) that are indicated for slowing down progression of kidney disease are often associated with hyperkalemia which becomes a limiting factor in their use and titration to the maximum dose. Having a safe, effective, tolerable, and affordable potassium binder can help optimize RAAS inhibition in the setting of kidney disease.AREAS COVERED: Although sodium po...
Source: Expert Review of Clinical Pharmacology - July 6, 2021 Category: Drugs & Pharmacology Authors: Anjay Rastogi Ramy M Hanna Anita Mkrttchyan Maham Khalid Sinan Yaqoob Kelly Shaffer Puneet Dhawan Niloofar Nobakht Mohammad Kamgar Ray Goshtaseb Kristine Sarmosyan Mariarosaria Gnarini Olivia Wassef Edgar Lerma Source Type: research

Immunotherapy of high risk non-muscle invasive bladder cancer
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1950531. Online ahead of print.ABSTRACTINTRODUCTION: Bladder cancer remains a prevalent and often lethal cancer. Fortunately, recent clinical trials using immunotherapeutics demonstrate promise to improve treatment outcomes. Several of these immunotherapies have already established their value in the metastatic space and likely will soon have indications in the non-metastatic space.AREAS COVERED: This review will cover immunotherapies ranging for well-studied BCG administration to more novel medications such as PD-L1/PD-1 inhibitors, CTLA-4 inhibitors, IL-1...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Michael Ahdoot Dan Theodorescu Source Type: research

Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1949286. Online ahead of print.ABSTRACTIntroduction: Tocilizumab is one of the main repurposed therapies investigated for COVID-19 pneumonia since the start of the pandemic, but there has been conflicting evidence for its use.Areas covered: This review covers the physiology of interleukin-6 and its role in the pathophysiology of COVID-19. We discuss the use of tocilizumab in other diseases and the rationale for its use in COVID-19. We summarize the design, contrasting results and implications of the clinical trials of tocilizumab in COVID-19 to date and dis...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Grace Kenny Patrick W G Mallon Source Type: research

A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose
This article reviews these alternative treatment regimens and intends to offer a detailed assessment of the available options to assist providers in managing cases of acetaminophen overdose.AREAS COVERED: This review article covers observational and experimental studies that assessed the efficacy and safety of alternative intravenous acetylcysteine regimens for acetaminophen overdose. A literature search was conducted using PubMed, ProQuest, and Scopus to identify the studies, which included results through April 2021. The assessment of alternative regimens consists of a discussion on the limitations and benefits, barriers...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Kevin Burnham Tianrui Yang Haleigh Smith Steven Knight Source Type: research

Immunotherapy of high risk non-muscle invasive bladder cancer
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1950531. Online ahead of print.ABSTRACTINTRODUCTION: Bladder cancer remains a prevalent and often lethal cancer. Fortunately, recent clinical trials using immunotherapeutics demonstrate promise to improve treatment outcomes. Several of these immunotherapies have already established their value in the metastatic space and likely will soon have indications in the non-metastatic space.AREAS COVERED: This review will cover immunotherapies ranging for well-studied BCG administration to more novel medications such as PD-L1/PD-1 inhibitors, CTLA-4 inhibitors, IL-1...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Michael Ahdoot Dan Theodorescu Source Type: research

Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1949286. Online ahead of print.ABSTRACTIntroduction: Tocilizumab is one of the main repurposed therapies investigated for COVID-19 pneumonia since the start of the pandemic, but there has been conflicting evidence for its use.Areas covered: This review covers the physiology of interleukin-6 and its role in the pathophysiology of COVID-19. We discuss the use of tocilizumab in other diseases and the rationale for its use in COVID-19. We summarize the design, contrasting results and implications of the clinical trials of tocilizumab in COVID-19 to date and dis...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Grace Kenny Patrick W G Mallon Source Type: research

A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose
This article reviews these alternative treatment regimens and intends to offer a detailed assessment of the available options to assist providers in managing cases of acetaminophen overdose.AREAS COVERED: This review article covers observational and experimental studies that assessed the efficacy and safety of alternative intravenous acetylcysteine regimens for acetaminophen overdose. A literature search was conducted using PubMed, ProQuest, and Scopus to identify the studies, which included results through April 2021. The assessment of alternative regimens consists of a discussion on the limitations and benefits, barriers...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Kevin Burnham Tianrui Yang Haleigh Smith Steven Knight Source Type: research

Immunotherapy of high risk non-muscle invasive bladder cancer
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1950531. Online ahead of print.ABSTRACTINTRODUCTION: Bladder cancer remains a prevalent and often lethal cancer. Fortunately, recent clinical trials using immunotherapeutics demonstrate promise to improve treatment outcomes. Several of these immunotherapies have already established their value in the metastatic space and likely will soon have indications in the non-metastatic space.AREAS COVERED: This review will cover immunotherapies ranging for well-studied BCG administration to more novel medications such as PD-L1/PD-1 inhibitors, CTLA-4 inhibitors, IL-1...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Michael Ahdoot Dan Theodorescu Source Type: research

Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1949286. Online ahead of print.ABSTRACTIntroduction: Tocilizumab is one of the main repurposed therapies investigated for COVID-19 pneumonia since the start of the pandemic, but there has been conflicting evidence for its use.Areas covered: This review covers the physiology of interleukin-6 and its role in the pathophysiology of COVID-19. We discuss the use of tocilizumab in other diseases and the rationale for its use in COVID-19. We summarize the design, contrasting results and implications of the clinical trials of tocilizumab in COVID-19 to date and dis...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Grace Kenny Patrick W G Mallon Source Type: research

A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose
This article reviews these alternative treatment regimens and intends to offer a detailed assessment of the available options to assist providers in managing cases of acetaminophen overdose.AREAS COVERED: This review article covers observational and experimental studies that assessed the efficacy and safety of alternative intravenous acetylcysteine regimens for acetaminophen overdose. A literature search was conducted using PubMed, ProQuest, and Scopus to identify the studies, which included results through April 2021. The assessment of alternative regimens consists of a discussion on the limitations and benefits, barriers...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Kevin Burnham Tianrui Yang Haleigh Smith Steven Knight Source Type: research

Immunotherapy of high risk non-muscle invasive bladder cancer
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1950531. Online ahead of print.ABSTRACTINTRODUCTION: Bladder cancer remains a prevalent and often lethal cancer. Fortunately, recent clinical trials using immunotherapeutics demonstrate promise to improve treatment outcomes. Several of these immunotherapies have already established their value in the metastatic space and likely will soon have indications in the non-metastatic space.AREAS COVERED: This review will cover immunotherapies ranging for well-studied BCG administration to more novel medications such as PD-L1/PD-1 inhibitors, CTLA-4 inhibitors, IL-1...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Michael Ahdoot Dan Theodorescu Source Type: research

Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1949286. Online ahead of print.ABSTRACTIntroduction: Tocilizumab is one of the main repurposed therapies investigated for COVID-19 pneumonia since the start of the pandemic, but there has been conflicting evidence for its use.Areas covered: This review covers the physiology of interleukin-6 and its role in the pathophysiology of COVID-19. We discuss the use of tocilizumab in other diseases and the rationale for its use in COVID-19. We summarize the design, contrasting results and implications of the clinical trials of tocilizumab in COVID-19 to date and dis...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Grace Kenny Patrick W G Mallon Source Type: research

A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose
This article reviews these alternative treatment regimens and intends to offer a detailed assessment of the available options to assist providers in managing cases of acetaminophen overdose.AREAS COVERED: This review article covers observational and experimental studies that assessed the efficacy and safety of alternative intravenous acetylcysteine regimens for acetaminophen overdose. A literature search was conducted using PubMed, ProQuest, and Scopus to identify the studies, which included results through April 2021. The assessment of alternative regimens consists of a discussion on the limitations and benefits, barriers...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Kevin Burnham Tianrui Yang Haleigh Smith Steven Knight Source Type: research

Immunotherapy of high risk non-muscle invasive bladder cancer
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1950531. Online ahead of print.ABSTRACTINTRODUCTION: Bladder cancer remains a prevalent and often lethal cancer. Fortunately, recent clinical trials using immunotherapeutics demonstrate promise to improve treatment outcomes. Several of these immunotherapies have already established their value in the metastatic space and likely will soon have indications in the non-metastatic space.AREAS COVERED: This review will cover immunotherapies ranging for well-studied BCG administration to more novel medications such as PD-L1/PD-1 inhibitors, CTLA-4 inhibitors, IL-1...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Michael Ahdoot Dan Theodorescu Source Type: research

Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date
Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1949286. Online ahead of print.ABSTRACTIntroduction: Tocilizumab is one of the main repurposed therapies investigated for COVID-19 pneumonia since the start of the pandemic, but there has been conflicting evidence for its use.Areas covered: This review covers the physiology of interleukin-6 and its role in the pathophysiology of COVID-19. We discuss the use of tocilizumab in other diseases and the rationale for its use in COVID-19. We summarize the design, contrasting results and implications of the clinical trials of tocilizumab in COVID-19 to date and dis...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Grace Kenny Patrick W G Mallon Source Type: research

A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose
This article reviews these alternative treatment regimens and intends to offer a detailed assessment of the available options to assist providers in managing cases of acetaminophen overdose.AREAS COVERED: This review article covers observational and experimental studies that assessed the efficacy and safety of alternative intravenous acetylcysteine regimens for acetaminophen overdose. A literature search was conducted using PubMed, ProQuest, and Scopus to identify the studies, which included results through April 2021. The assessment of alternative regimens consists of a discussion on the limitations and benefits, barriers...
Source: Expert Review of Clinical Pharmacology - June 30, 2021 Category: Drugs & Pharmacology Authors: Kevin Burnham Tianrui Yang Haleigh Smith Steven Knight Source Type: research

Recent advances and future perspectives in the pharmacological treatment of < em > Candida auris < /em > infections
Expert Rev Clin Pharmacol. 2021 Jun 26. doi: 10.1080/17512433.2021.1949285. Online ahead of print.ABSTRACTINTRODUCTION: Candida auris is responsible for hospital outbreaks worldwide. Some C. auris isolates may show concomitant resistance to azoles, echinocandins, and polyenes, thereby possibly leaving clinicians with few therapeutic options.AREAS COVERED: Antifungal agents both in early and in late phases of clinical development showing anti-C. auris activity.EXPERT OPINION: The research on antifungal agents active against C. auris has made important steps forward in recent years: (i) the development of drugs with novel me...
Source: Expert Review of Clinical Pharmacology - June 28, 2021 Category: Drugs & Pharmacology Authors: Daniele R Giacobbe Laura Magnasco Chiara Sepulcri Malgorzata Mikulska Philipp Koehler Oliver A Cornely Matteo Bassetti Source Type: research

Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide
Expert Rev Clin Pharmacol. 2021 Jun 28:1-10. doi: 10.1080/17512433.2021.1938549. Online ahead of print.ABSTRACTBackground: Arsenic trioxide (ATO) was successfully applied to treat acute promyelocytic leukemia (APL).Methods: Inorganic arsenic (iAs), monomethylarsonic acid (MMAV) and dimethyarsinic acid (DMAV) in plasma of 143 APL patients with different renal function were determined. Arsenic methylation capacity was evaluated by iAs%, MMAV%, DMAV%, primary methylation index (PMI, MMAV/iAs), and secondary methylated index (SMI, DMAV/MMAV). Arsenic accumulation with administration frequency were explored. Moreover, safety as...
Source: Expert Review of Clinical Pharmacology - June 28, 2021 Category: Drugs & Pharmacology Authors: Qilei Zhao Meihua Guo Thomas H Hostetter Hongzhu Chen Liwang Lin Xin Hai Source Type: research

Recent advances and future perspectives in the pharmacological treatment of < em > Candida auris < /em > infections
Expert Rev Clin Pharmacol. 2021 Jun 26. doi: 10.1080/17512433.2021.1949285. Online ahead of print.ABSTRACTINTRODUCTION: Candida auris is responsible for hospital outbreaks worldwide. Some C. auris isolates may show concomitant resistance to azoles, echinocandins, and polyenes, thereby possibly leaving clinicians with few therapeutic options.AREAS COVERED: Antifungal agents both in early and in late phases of clinical development showing anti-C. auris activity.EXPERT OPINION: The research on antifungal agents active against C. auris has made important steps forward in recent years: (i) the development of drugs with novel me...
Source: Expert Review of Clinical Pharmacology - June 28, 2021 Category: Drugs & Pharmacology Authors: Daniele R Giacobbe Laura Magnasco Chiara Sepulcri Malgorzata Mikulska Philipp Koehler Oliver A Cornely Matteo Bassetti Source Type: research

Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide
Expert Rev Clin Pharmacol. 2021 Jun 28:1-10. doi: 10.1080/17512433.2021.1938549. Online ahead of print.ABSTRACTBackground: Arsenic trioxide (ATO) was successfully applied to treat acute promyelocytic leukemia (APL).Methods: Inorganic arsenic (iAs), monomethylarsonic acid (MMAV) and dimethyarsinic acid (DMAV) in plasma of 143 APL patients with different renal function were determined. Arsenic methylation capacity was evaluated by iAs%, MMAV%, DMAV%, primary methylation index (PMI, MMAV/iAs), and secondary methylated index (SMI, DMAV/MMAV). Arsenic accumulation with administration frequency were explored. Moreover, safety as...
Source: Expert Review of Clinical Pharmacology - June 28, 2021 Category: Drugs & Pharmacology Authors: Qilei Zhao Meihua Guo Thomas H Hostetter Hongzhu Chen Liwang Lin Xin Hai Source Type: research

Recent advances and future perspectives in the pharmacological treatment of < em > Candida auris < /em > infections
Expert Rev Clin Pharmacol. 2021 Jun 26. doi: 10.1080/17512433.2021.1949285. Online ahead of print.ABSTRACTINTRODUCTION: Candida auris is responsible for hospital outbreaks worldwide. Some C. auris isolates may show concomitant resistance to azoles, echinocandins, and polyenes, thereby possibly leaving clinicians with few therapeutic options.AREAS COVERED: Antifungal agents both in early and in late phases of clinical development showing anti-C. auris activity.EXPERT OPINION: The research on antifungal agents active against C. auris has made important steps forward in recent years: (i) the development of drugs with novel me...
Source: Expert Review of Clinical Pharmacology - June 28, 2021 Category: Drugs & Pharmacology Authors: Daniele R Giacobbe Laura Magnasco Chiara Sepulcri Malgorzata Mikulska Philipp Koehler Oliver A Cornely Matteo Bassetti Source Type: research

Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?
Expert Rev Clin Pharmacol. 2021 Jun 15. doi: 10.1080/17512433.2021.1944102. Online ahead of print.NO ABSTRACTPMID:34130583 | DOI:10.1080/17512433.2021.1944102 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - June 16, 2021 Category: Drugs & Pharmacology Authors: Tu ğrul Elverdi Melis Dila Özer Çerme Tahacan Ayd ın Ahmet Emre E şkazan Source Type: research